GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Cyclically Adjusted PB Ratio

ANIK (Anika Therapeutics) Cyclically Adjusted PB Ratio : 0.55 (As of May. 29, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Anika Therapeutics's current share price is $11.26. Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $20.44. Anika Therapeutics's Cyclically Adjusted PB Ratio for today is 0.55.

The historical rank and industry rank for Anika Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ANIK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.54   Med: 2.73   Max: 6.72
Current: 0.54

During the past years, Anika Therapeutics's highest Cyclically Adjusted PB Ratio was 6.72. The lowest was 0.54. And the median was 2.73.

ANIK's Cyclically Adjusted PB Ratio is ranked better than
84.64% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs ANIK: 0.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anika Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $10.352. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $20.44 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anika Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Anika Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cyclically Adjusted PB Ratio Chart

Anika Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.14 2.15 1.58 1.14 0.81

Anika Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.25 1.24 1.21 0.81 0.74

Competitive Comparison of Anika Therapeutics's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Anika Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Anika Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.26/20.44
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Anika Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.352/134.9266*134.9266
=10.352

Current CPI (Mar. 2025) = 134.9266.

Anika Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 12.701 100.684 17.021
201509 13.306 100.392 17.883
201512 14.022 99.792 18.959
201603 13.229 100.470 17.766
201606 13.832 101.688 18.353
201609 14.672 101.861 19.435
201612 15.230 101.863 20.174
201703 15.696 102.862 20.589
201706 16.656 103.349 21.745
201709 17.275 104.136 22.383
201712 17.939 104.011 23.271
201803 17.889 105.290 22.924
201806 16.909 106.317 21.459
201809 17.962 106.507 22.755
201812 18.551 105.998 23.614
201903 18.930 107.251 23.815
201906 18.204 108.070 22.728
201909 19.741 108.329 24.588
201912 20.155 108.420 25.082
202003 20.686 108.902 25.630
202006 20.307 108.767 25.191
202009 20.020 109.815 24.598
202012 19.010 109.897 23.340
202103 19.258 111.754 23.251
202106 19.892 114.631 23.414
202109 20.093 115.734 23.425
202112 19.880 117.630 22.803
202203 19.685 121.301 21.896
202206 19.602 125.017 21.156
202209 19.507 125.227 21.018
202212 19.526 125.222 21.039
202303 18.831 127.348 19.952
202306 18.695 128.729 19.595
202309 18.480 129.860 19.201
202312 14.479 129.419 15.095
202403 14.070 131.776 14.406
202406 14.175 132.554 14.429
202409 12.241 133.029 12.416
202412 10.682 133.157 10.824
202503 10.352 134.927 10.352

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anika Therapeutics  (NAS:ANIK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Anika Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767